hCD19TGTg/0 recipient mice injected with 300 mg/kg of cyclophosphamide (Cy) a day prior to adoptive cell transfer (ACT) with C57BL/6 hCAR19 or tEGFR Tregs, or hCAR19 or tEGFR CD8+ T cells (CTL). (A) Representative flow cytometry plots and quantification (B) of hCD19+ lymphocytes in the spleen on day 5 after ACT. Cy, n = 4; hCAR19 CD8+ CTLs, n = 3; tEGFR CD8+ CTLs, n = 3; hCAR19 Tregs, n = 4; tEGFR Tregs, n = 3. Data are representative from 2 independent experiments. (C) Survival. (D) Percentage body weight. (E) Clinical scores. Unmanipulated, n = 4; Cy, n = 4; hCAR19 CD8+ CTLs, n = 4; tEGFR CD8+ CTLs, n = 3; hCAR19 Tregs, n = 3; tEGFR Tregs, n = 3. Data are representative of 3 independent experiments. Statistics are shown on day 5 after ACT. Student’s t test with Bonferroni correction for multiple comparison was used for statistical analysis. Log rank test was used to analyze survival curves. Error bars indicate the standard deviation of the mean. *: P < 0.5; **: P < 0.01; ****: P < 0.0001.